blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3936142

EP3936142 - TRIPLE AGONIST HAVING ACTIVITY WITH RESPECT TO ALL OF GLUCAGON, GLP-1, AND GIP RECEPTORS FOR TREATING LIVER DISEASE [Right-click to bookmark this link]
Former [2022/02]THERAPEUTIC USE, FOR LIVER DISEASE, OF TRIPLE AGONIST HAVING ACTIVITY WITH RESPECT TO ALL OF GLUCAGON, GLP-1, AND GIP RECEPTORS, OR CONJUGATE THEREOF
[2023/35]
StatusThe patent has been granted
Status updated on  15.12.2023
Database last updated on 14.11.2024
FormerGrant of patent is intended
Status updated on  21.08.2023
FormerRequest for examination was made
Status updated on  10.12.2021
FormerThe international publication has been made
Status updated on  15.01.2021
Most recent event   Tooltip01.11.2024Lapse of the patent in a contracting state
New state(s): SK		published on 04.12.2024 [2024/49]
Applicant(s)For all designated states
Hanmi Pharm. Co., Ltd.
214 Muha-ro
Paltan-myeon
Hwaseong-si, Gyeonggi-do 18536 / KR
[2022/02]
Inventor(s)01 / KWON, Hyun Joo
550, Dongtangiheung-ro
Hwaseong-si, Gyeonggi-do 18469 / KR
02 / KIM, Jung Kuk
550, Dongtangiheung-ro
Hwaseong-si, Gyeonggi-do 18469 / KR
03 / PARK, Eun Jin
550, Dongtangiheung-ro
Hwaseong-si, Gyeonggi-do 18469 / KR
04 / LEE, Jong Min
550, Dongtangiheung-ro
Hwaseong-si, Gyeonggi-do 18469 / KR
05 / LEE, Jong Suk
550, Dongtangiheung-ro
Hwaseong-si, Gyeonggi-do 18469 / KR
06 / JO, Hyo Sang
550, Dongtangiheung-ro
Hwaseong-si, Gyeonggi-do 18469 / KR
07 / CHOI, In Young
550, Dongtangiheung-ro
Hwaseong-si, Gyeonggi-do 18469 / KR
 [2024/03]
Former [2022/02]01 / KWON, Hyun Joo
Hwaseong-si, Gyeonggi-do 18469 / KR
02 / KIM, Jung Kuk
Hwaseong-si, Gyeonggi-do 18469 / KR
03 / PARK, Eun Jin
Hwaseong-si, Gyeonggi-do 18469 / KR
04 / LEE, Jong Min
Hwaseong-si, Gyeonggi-do 18469 / KR
05 / LEE, Jong Suk
Hwaseong-si, Gyeonggi-do 18469 / KR
06 / JO, Hyo Sang
Hwaseong-si, Gyeonggi-do 18469 / KR
07 / CHOI, In Young
Hwaseong-si, Gyeonggi-do 18469 / KR
Representative(s)Mewburn Ellis LLP
Aurora Building
Counterslip
Bristol BS1 6BX / GB
[2022/02]
Application number, filing date20832900.329.06.2020
[2022/02]
WO2020KR08479
Priority number, dateKR2019007777628.06.2019         Original published format: KR 20190077776
KR2020000438613.01.2020         Original published format: KR 20200004386
KR2020000437913.01.2020         Original published format: KR 20200004379
KR2020006921908.06.2020         Original published format: KR 20200069219
[2022/02]
Filing languageKO
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2020263063
Date:30.12.2020
Language:KO
[2020/53]
Type: A1 Application with search report 
No.:EP3936142
Date:12.01.2022
Language:EN
[2022/02]
Type: B1 Patent specification 
No.:EP3936142
Date:17.01.2024
Language:EN
[2024/03]
Search report(s)International search report - published on:KR30.12.2020
(Supplementary) European search report - dispatched on:EP01.12.2022
ClassificationIPC:A61K38/17, A61P1/16, A61K47/68, A61P29/00, A61P35/00
[2022/52]
CPC:
A61K38/1796 (EP,CN,IL,KR,US); A61K38/26 (CN,IL,KR); A61K47/60 (CN,IL);
A61K47/68 (EP,IL); A61K47/6811 (EP,CN,IL,US); A61K47/6847 (IL,KR);
A61P1/16 (EP,CN,IL,KR,US); A61P29/00 (CN,IL); A61P35/00 (CN,IL) (-)
Former IPC [2022/02]A61K38/17, A61P1/16
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2022/02]
Extension statesBANot yet paid
MENot yet paid
Validation statesKHNot yet paid
MANot yet paid
MDNot yet paid
TNNot yet paid
TitleGerman:TRIPLE-AGONISTEN MIT AKTIVITÄT IN BEZUG AUF ALLE GLUCAGON-, GLP-1- UND GIP-REZEPTOREN ODER ZUR BEHANDLUNG VON LEBERERKRANKUNG[2023/35]
English:TRIPLE AGONIST HAVING ACTIVITY WITH RESPECT TO ALL OF GLUCAGON, GLP-1, AND GIP RECEPTORS FOR TREATING LIVER DISEASE[2023/35]
French:TRIPLE AGONISTE AYANT UNE ACTIVITÉ PAR RAPPORT À TOUS LES RÉCEPTEURS DU GLUCAGON, DE GLP-1 ET DE GIP POUR TRAITEMENT DE MALADIES HÉPATHIQUES[2023/35]
Former [2022/02]THERAPEUTISCHE VERWENDUNG VON TRIPLE-AGONISTEN MIT AKTIVITÄT IN BEZUG AUF ALLE GLUCAGON-, GLP-1- UND GIP-REZEPTOREN ODER KONJUGAT DAVON FÜR LEBERERKRANKUNG
Former [2022/02]THERAPEUTIC USE, FOR LIVER DISEASE, OF TRIPLE AGONIST HAVING ACTIVITY WITH RESPECT TO ALL OF GLUCAGON, GLP-1, AND GIP RECEPTORS, OR CONJUGATE THEREOF
Former [2022/02]UTILISATION THÉRAPEUTIQUE, POUR LES MALADIES HÉPATHIQUES, D'UN TRIPLE AGONISTE AYANT UNE ACTIVITÉ PAR RAPPORT À TOUS LES RÉCEPTEURS DU GLUCAGON, DE GLP-1 ET DE GIP, OU CONJUGUÉ DE CEUX-CI
Entry into regional phase16.04.2021Translation filed 
16.04.2021National basic fee paid 
16.04.2021Search fee paid 
16.04.2021Designation fee(s) paid 
16.04.2021Examination fee paid 
Examination procedure16.04.2021Examination requested  [2022/02]
09.05.2023Amendment by applicant (claims and/or description)
22.08.2023Communication of intention to grant the patent
13.12.2023Fee for grant paid
13.12.2023Fee for publishing/printing paid
13.12.2023Receipt of the translation of the claim(s)
Divisional application(s)EP23215168.8  / EP4311578
Fees paidRenewal fee
27.06.2022Renewal fee patent year 03
21.06.2023Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipBG17.01.2024
EE17.01.2024
HR17.01.2024
LT17.01.2024
LV17.01.2024
SK17.01.2024
SM17.01.2024
RS17.04.2024
IS17.05.2024
[2024/49]
Former [2024/48]BG17.01.2024
EE17.01.2024
HR17.01.2024
LT17.01.2024
LV17.01.2024
SM17.01.2024
RS17.04.2024
IS17.05.2024
Former [2024/47]BG17.01.2024
HR17.01.2024
LT17.01.2024
LV17.01.2024
SM17.01.2024
RS17.04.2024
IS17.05.2024
Former [2024/36]BG17.01.2024
HR17.01.2024
LT17.01.2024
LV17.01.2024
RS17.04.2024
IS17.05.2024
Former [2024/35]BG17.01.2024
HR17.01.2024
LT17.01.2024
RS17.04.2024
IS17.05.2024
Former [2024/33]LT17.01.2024
IS17.05.2024
Former [2024/32]IS17.05.2024
Documents cited:Search[Y]US2018311315  (OH EUH LIM [KR], et al);
International search[Y]KR20150023013  (UNIV INDIANA RES & TECH CORP [US]);
 [A]WO2016198624  (SANOFI SA [FR]);
 [A]KR20170003466  (HANMI PHARM IND CO LTD [KR]);
 [Y]KR20170080522  (HANMI PHARM IND CO LTD [KR]);
 [A]KR20180053747  (LILLY CO ELI [US])
by applicantWO9632478
 WO9734631
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.